Solid Tumor Clinical Trials in Houston, Texas

36 studies are recruiting for solid tumor in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

2. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

   This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 0103, Houston, Texas

   Locations

   24 in total

   Run by

   K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

   See if you can join NCT04516447 on ClinicalTrials.gov

3. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology, Houston, Texas

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

4. Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

   The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, a…

   Stage

   Phase 2

   Ages

   1 to 30

   Site

   Texas Children's Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   Emory University

   See if you can join NCT04469530 on ClinicalTrials.gov

5. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

   This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor St. Luke's Medical Center, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT03740256 on ClinicalTrials.gov

6. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

   This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   OnCusp Therapeutics, Inc.

   See if you can join NCT06234423 on ClinicalTrials.gov

7. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov

8. BP1001-A in Patients With Advanced or Recurrent Solid Tumors

   This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is es…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   4 in total

   Run by

   Bio-Path Holdings, Inc.

   See if you can join NCT04196257 on ClinicalTrials.gov

9. Trial of DFP-14927 in Advanced Solid Tumors

   This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   2 in total

   Run by

   Delta-Fly Pharma, Inc.

   See if you can join NCT03943004 on ClinicalTrials.gov

10. A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

    The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    BridGene Biosciences Inc.

    See if you can join NCT06452160 on ClinicalTrials.gov

11. Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

    Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics [='PD']) * What does the body do to study drug (how processed in body (Pharmacokinetics [='PK']) - Safety Study drug by intravenous …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    4 in total

    Run by

    Qualigen Theraputics, Inc.

    See if you can join NCT06086522 on ClinicalTrials.gov